Vatalanib for metastatic gastrointestinal stromal tumour (GIST) resistant to imatinib: final results of a phase II study

BACKGROUND: Vatalanib (PTK787/ZK 222584) inhibits a few tyrosine kinases including KIT, platelet-derived growth factor receptors (PDGFRs) and vascular endothelial growth factor receptors (VEGFRs). We report efficacy and safety results of vatalanib in advanced gastrointestinal stromal tumour (GIST) r...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Joensuu, H, De Braud, F, Grignagni, G, De Pas, T, Spitalieri, G, Coco, P, Spreafico, C, Boselli, S, Toffalorio, F, Bono, P, Jalava, T, Kappeler, C, Aglietta, M, Laurent, D, Casali, P G
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group 2011
Assuntos:
Clinical Study
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3111164/
https://ncbi.nlm.nih.gov/pubmed/21540861
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2011.151
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados